Gordon Research Conferences

Board of Trustees

The GRC Board of Trustees (BOT) consists of thirteen members. Annually, at its spring meeting, the Board of Trustees nominates at least four persons who are members of the Council, past members of the Conference Evaluation Committee or past Chairs of a Conference as candidates for Trusteeship. In making such nominations, the Board gives due consideration to the desirability of the membership of the full Board representing on a continuing basis the various major geographic areas and disciplines of the scientific community. From this slate, within sixty days after the nomination, the Council elects two Trustees by ballot, for terms of six years each. Elected Trustees may be reselected for additional terms but are not eligible to serve for consecutive six year terms. Their terms begin upon the final adjournment of the meeting of the Board of Trustees next after August 1 of each year. In addition, the executive officer of the American Association for the Advancement of Science (AAAS), or such officer's delegate, serves as a Trustee.

Member List:

Frances Platt (Chair)
University of Oxford

Term: November 2012-2018

Frances M. Platt is Professor of Biochemistry and Pharmacology in the Department of Pharmacology, University of Oxford, UK. She received her Ph.D. in Animal Physiology from the University of Bath, UK. After completing postdoctoral training at Washington University Medical School, St. Louis, she joined the faculty at the University of Oxford and was the recipient of a five-year Lister Institute Senior Research Fellowship. Her expertise relates to glycosphingolipids (GSL) and in particular glycosphingolipid (GSL) lysosomal storage diseases. She and her colleagues pioneered a novel approach to treat these inherited diseases that has led to the development of an approved drug (miglustat) for type 1 Gaucher disease and Niemann-Pick disease type C1 disease. She was awarded the Alan Gordon Memorial award from the UK Gaucher Association and the Horst-Bickel Award in recognition of her role in developing substrate reduction therapy for lysosomal disorders. She has published extensively in this field over the past 20 years and co-edited a book titled Lysosomal Disorders of the Brain. Platt is currently an Editor for the Journal of Biological Chemistry (2009-2014) and serves on the advisory board of multiple lysosomal storage disease charities and organizations (UK and USA). She was elected Fellow of the Academy of Medical Sciences in 2011. She has attended many Gordon Research Conferences and will serve as Chair of the Lysosomal Diseases GRC in 2013. Platt states, "The creation of the GRS program is a real innovation and will ensure a very bright future for the GRC meetings in the years to come. I am particularly excited about how the GRS scheme can evolve over the next 5 years to maximize junior attendee empowerment and participation at GRCs and to encompass a much broader participation from scientists in countries who currently have no tradition of GRC participation".

Meigan Aronson (Vice Chair)
Texas A&M University

Term: November 2013-2019

Meigan Aronson is the Dean of Science at Texas A&M University. Previously she was a Professor in the Department of Physics and Astronomy at Stony Brook University, as well as a Group Leader in the Condensed Matter Physics and Materials Science Department at Brookhaven National Laboratory. She received her B.A. in Physics from Bryn Mawr College, and a M.S. and Ph.D. in Physics from the University of Illinois at Urbana-Champaign. After postdoctoral work at Los Alamos National Laboratory and a Visiting Scientist position at the University of Amsterdam, she joined the faculty of the Physics Department at the University of Michigan. After receiving tenure in 1996, and being promoted to Professor of Physics in 2000, she served as Associate Dean for Natural Sciences in the College of Literature, Science, and Arts from 2004-2006. She assumed her current appointments at Stony Brook and Brookhaven in 2007. Her research in experimental condensed matter physics focuses on the interplay of superconductivity and magnetism and the role of quantum phase transitions in systems with strong electronic correlations. Aronson has received the CIC Academic Leadership and the National Security Science and Engineering Faculty Fellowships, and is a Fellow of the American Physical Society. She currently serves on the Editorial Board of the Annual Reviews in Condensed Matter Physics, the Board of Governors for the Institute for Complex and Adaptive Matter, and on a number of advisory boards including the National High Magnetic Field Laboratory and the Spallation Neutron Source, the latter as chair. Aronson states, "The Gordon Research Conferences provide a unique and much needed venue for the discussion of emerging ideas, accessible to students and senior researchers alike. Diversity of ideas is key to scientific progress, and the GRC's success in selecting both new and established topics that appeal to a broad and international audience must be protected and advanced".

Susan L. Hamilton (Past Chair)
Baylor College of Medicine

Term: November 2011-2017

Susan L. Hamilton is Professor and Chair of the Department of Molecular Physiology and Biophysics at Baylor College of Medicine. She also holds the L.F. McCollum Chair in Molecular Physiology. She received her Ph.D. in Biophysics from the University of Colorado Medical School. After completing postdoctoral training at Columbia University, College of Physicians and Surgeons, she joined the faculty at the University of Texas Medical Branch before moving to the Department of Molecular Physiology and Biophysics at Baylor College of Medicine where she has been Chair since 2000. The research in the Hamilton lab centers around defining the mechanisms that control of intracellular Ca2+ and oxidative/nitrosative stress in skeletal muscle and defining how alterations in these processes lead to human disease. This research is dedicated to elucidating the mechanisms underlying the ryanodine receptor myopathies, which are a wide spectrum of muscle disorders ranging from enhanced susceptibility to heat stroke to disabling mitochondrial myopathies such as central core disease (CCD). A major goal of the laboratory is to develop new therapeutic interventions. Hamilton has attended many Gordon Research Conferences and served as Chair of the Muscle: Excitation-Contraction Coupling Gordon Conference in 2006. She recognizes the high impact of these conferences in a variety of scientific disciplines and in promoting the careers of young investigators. Hamilton states, "The GRC forum for the open exchange of scientific data and ideas has been and will continue to be extremely valuable to scientific advancement and to the growth of collaborative science. These conferences help to promote new ideas, challenge dogma, and expand scientific boundaries. Future conferences should strive to bring together scientists representing different disciplines and should be very flexible to reflect scientific progress in new developing fields".

Catherine Kallin
University of California, Santa Barbara

Term: November 2011-2017

Catherine Kallin is a Professor of Physics and holds a Canada Research Chair in Quantum Materials Theory at McMaster University. She received her B.S. in Physics and Mathematics from the University of British Columbia and her Ph.D. in Theoretical Condensed Matter Physics from Harvard University. After postdoctoral work at the Institute for Theoretical Physics in Santa Barbara, she joined the faculty at McMaster in 1986. Her research is focused on understanding novel electron behavior in materials, including unconventional superconductors, frustrated magnets and quantum Hall systems. Kallin has held Sloan and Guggenheim Fellowships and is a Fellow of the American Physical Society. She currently serves on the Advisory Board of the School for Condensed Matter Physics in Boulder, and has served on the Advisory Boards for the Aspen Center for Physics, Kavli Institute for Theoretical Physics, and TRIUMF, among others, in the past. Kallin states, "I have benefitted from the lively discussion of new results at Gordon Research Conferences, both as a graduate student and as a senior faculty member, and have witnessed the participation become more global and diverse. The GRC should strive to maintain and enhance this diversity in participants, as well as in topics, ensuring the needs of both established research areas and newly emerging areas are met".

Eleanore T. Wurtzel
Lehman College, City University of New York

Term: November 2012-2018

Eleanore Wurtzel is Professor of Biological Sciences at Lehman College, The City University of New York, Chair of the CUNY Plant Sciences Ph.D. subprogram and on the Biology and Biochemistry Doctoral faculty. She holds a B.S. in Biochemistry and Ph.D. in Molecular Biology from SUNY Stony Brook where she conducted pioneering work on the first two-component signal transduction system in bacteria. Wurtzel switched to plant biology with postdoctoral stays at Brookhaven National Laboratory and Cold Spring Harbor Laboratory. Wurtzel’s research on plant provitamin A carotenoids supports development of sustainable solutions to global vitamin A deficiency and has been funded by NIH, Rockefeller Foundation, American Cancer Society, McKnight Foundation, and NSF. For long-standing contributions to carotenoid research and to the scientific community, Wurtzel was elected a AAAS fellow (2006) and is being awarded Fellow of ASPB by the American Society of Plant Biologists (2012). Wurtzel founded and chaired the first GRC on Plant Metabolic Engineering and its first Gordon Research Seminar (GRS). She co-organized the 2010 GRC on Carotenoids, will chair the 2013 meeting and founded its new GRS. Since 2007, Wurtzel has served on the GRC Conference Evaluation Committee to advise on the conference portfolio, evaluate new conference proposals, and recommend the prestigious Alexander Cruickshank Lecturer Awards. Wurtzel recognizes the importance of promoting diversity in science, experience she brings as a faculty member of a minority-serving institution. Wurtzel states, "The GRC should continue to be committed to enhancing diversity and growth of scientific communities by engaging junior investigators. Research collaborations in an era of electronic social networks and scientific globalization will be independent of geographical and physical boundaries. It is essential that the GRC keep pace with new opportunities born of emerging fields and facilitate the necessary interdisciplinary conversations that will catapult new discoveries".

Joseph S. Francisco
University of Nebraska-Lincoln

Term: November 2013-2019

Joseph S. Francisco is a Distinguished Professor of Earth and Atmospheric Science and Chemistry and Associate Dean of Research and Graduate Studies at Purdue University. He received his B.S. at the University of Texas, Austin, and he received his Ph.D. from Massachusetts Institute of Technology. Francisco was a Research Fellow at Cambridge University in England, and a Visiting Associate in Planetary Science at California Institute of Technology. His research has focused on bringing new tools from experimental physical and theoretical chemistry to atmospheric chemical problems to enhance our understanding of chemistry in the atmosphere at the molecular level. This work has led to important discoveries of new chemistries occurring on the interfaces of cloud surfaces as well as fundamental new chemical bonding controlling these processes. He was awarded an Alexander von Humboldt U.S. Senior Scientist Award; appointed a Senior Visiting Fellow at the Institute of Advanced Studies at the University of Bologna, Italy; Professeur Invité at the Université de Paris-Est, France; a Visiting Professor at Uppsala Universitet, Sweden; and an Honorary International Chair Professor at National Taipei University, Taiwan. He served as President of the American Chemical Society in 2010. He is a member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. Francisco states, "Science across many disciplines is increasingly becoming more inter/multi-disciplinary and global. While this is creating unprecedented challenges, it also creates new opportunities. Venues that bring scientists together, from across the globe, will be important in stimulating disruptive innovation. Gordon Research Conferences is one such highly regarded international forum which must continue to examine how this venue can continue to foster exchanges, experiment with new formats aided by new technology to evolve the structure and operations of GRC to meet the global challenges of the science community".

Barry S. Cooperman
University of Pennsylvania

Term: November 2014-2020

Barry S. Cooperman is Professor of Chemistry at the University of Pennsylvania and is a member of the Board of Directors of Associated Universities Inc. (AUI), which manages the National Radio Astronomy Observatory as well as construction and North American Operations of the Atacama Large Millimeter Array (ALMA). He received a B.A. in Chemistry from Columbia University, a Ph.D. in Chemistry from Harvard University, and did a year of postdoctoral work at the Pasteur Institute (Paris) before coming to Penn as an Assistant Professor. During his time at Penn he has served as Vice Provost for Research for 13 years. He also has served as a member of the International Scientific Advisory Board of Max-Planck-Institut für Molekulare Genetik, Berlin, as Regional Editor for the journal Biochimie, and as Chairman of the Board of Trustees of AUI and of the Scientific Advisory Committee of the Wistar Institute. He is a Fellow of the American Association for the Advancement of Science and a Chevalier de l'Ordre des Palmes Académique. His research interests focus on mechanistic biochemistry, with particular emphasis on the enzymes inorganic pyrophosphatase and ribonucleotide reductase, on serine proteinase inhibitors (serpins) and, most recently, on protein translation. A major thrust in the latter area has been the development of fluorescent probes for both in vitro and in vivo monitoring of protein synthesis on the ribosome. Over the course of his career he has published more than 225 peer-reviewed papers and trained more than 80 graduate students and postdoctoral fellows. Cooperman has attended and spoken at many Gordon Research Conferences and values the opportunities for free, frank, and detailed discussions and exchanges of ideas that these Conferences provide. "The GRC have been invaluable as places where both young and more-established investigators can interact at an intimate and fundamental level, offering participants comprehensive perspectives of the contemporary states of their chosen fields. Going forward, it will be important to maintain this special atmosphere as new disciplines develop and the scientific community becomes ever more global."

Scott D. Emr
Weill Institute for Cell and Molecular Biology, Cornell University

Term: November 2014-2020

Scott Emr is Director of the Weill Institute for Cell and Molecular Biology at Cornell University. He holds the Frank H.T. Rhodes Professorship in the Department of Molecular Biology and Genetics (2007 - present). Emr received his Ph.D. in Molecular Genetics from Harvard University in 1981. Prior to joining the faculty at Cornell, Emr has held positions at the University of California, Berkeley (Miller Research Scholar), the California Institute of Technology (Assistant and Associate Professor) and the University of California, San Diego School of Medicine (Distinguished Professor and Investigator in the Howard Hughes Medical Institute). He has published more than 250 papers and trained over 80 graduate students and postdocs. He has participated in over 30 Gordon Research Conferences and chaired the Lysosomes and Endocytosis GRC. Emr’s research focuses on the regulation of cell signaling and membrane trafficking pathways by phosphoinositide lipids, ubiquitin modifications, and vesicle-mediated transport reactions. The Emr lab identified the first components (the ESCRT complexes) of the molecular machinery required for receptor down-regulation as well as the budding and release of the HIV virus. Emr has been elected a member of the National Academy of Sciences, the American Academy of Arts and Sciences and the American Academy of Microbiology. He was awarded the Hansen Foundation Gold Medal Prize for elucidating intracellular sorting and transport pathways and the Avanti Prize for his key contributions in understanding lipid signaling pathways. He has served as a member of the Advisory Boards for the Pew Scholars Program in Biomedical Sciences and the Searle Scholars Program. Emr states, "The GRC is a treasured program that has helped to shape the research and careers of countless scientists from around the world. These conferences encourage and inspire young graduate students and postdocs to dream of exciting futures of their own in research science. We need to ensure that the GRC remains a premier scientific program that anticipates and responds to the needs of the next generation of scientists and innovators."

Rush D. Holt
American Association for the Advancement of Science

Term: April 2015-2021

Rush D. Holt is the 18th chief executive officer of the American Association for the Advancement of Science (AAAS) and the executive publisher of the Science family of journals. In this role, Holt leads the world's largest multi-disciplinary scientific and engineering society. Over his long career, Dr. Holt has held positions as a teacher, scientist, administrator, and policymaker. From 1987 to 1998, Holt was assistant director of the Princeton Plasma Physics Laboratory (PPPL), a Department of Energy national lab, which is the largest research facility of Princeton University and one of the largest alternative energy research facilities in the country. At PPPL, Holt helped establish the lab's nationally renowned science education program. From 1980 to 1988, Holt served on the faculty of Swarthmore College, where he taught courses in physics and public policy. In 1982, he took leave from Swarthmore to serve as an AAAS/American Physical Society Science and Technology Policy Fellow on Capitol Hill. He also served as an arms control expert at the U.S. State Department, where he monitored the nuclear programs of countries such as Iraq, Iran, North Korea, and the former Soviet Union. In 1981, Holt was issued a patent for an improved solar-pond technology for harnessing energy from sunlight. Before coming to AAAS, Holt served for 16 years as a member of the U.S. House of Representatives, representing New Jersey's 12th Congressional District. In Congress, Holt served as a senior member of the Committee on Natural Resources and the Committee on Education and the Workforce. On Capitol Hill, Holt established a long track record of advocacy for federal investment in research and development, science education, and innovation. He served on the National Commission on the Teaching of Mathematics and Science (known as the Glenn Commission), founded the Congressional Research and Development Caucus, and served as a co-chair of the Biomedical Research Caucus. Holt served eight years on the Permanent Select Committee on Intelligence and, from 2007 to 2010, chaired the Select Intelligence Oversight Panel, which worked to strengthen legislative oversight of the intelligence community. His legislative work earned him numerous accolades, including being named one of Scientific American magazine's "50 National Visionaries Contributing to a Brighter Technological Future" and a "Champion of Science" by the Science Coalition. Holt is a Phi Beta Kappa graduate of Carleton College in Northfield, Minnesota, and he holds M.A. and Ph.D. degrees in physics from New York University. He is an elected fellow of AAAS, the American Physical Society, and Sigma Xi, and he holds honorary degrees from Monmouth University, Rider University, and Thomas Edison State College.

Dennis A. Dougherty
California Institute of Technology

Term: November 2015-2021

Dennis A. Dougherty is the George Grant Hoag Professor of Chemistry at the California Institute of Technology. Dougherty received his B.S. from Bucknell University, a Ph.D. from Princeton University, and did postdoctoral work at Yale University. Dougherty is a member of the National Academy of Sciences and has received numerous scientific awards. Dougherty has published over 200 articles and has delivered distinguished lectureships around the world. Dougherty has been recognized with several teaching awards at Caltech, including the Richard Feynman Prize. Dougherty is the co-author, with Professor Eric Anslyn, of the influential textbook, Modern Physical Organic Chemistry. Dougherty's research spans the disciplines from physical organic chemistry to chemical biology to neuroscience. Dougherty introduced the cation-π interaction, a powerful noncovalent binding interaction that is widely employed in both small molecule and macromolecular recognition in biology and chemistry. Dougherty's current research is focused on molecular neurobiology, applying the mindset and tools of physical organic chemistry to the complex proteins of neuroscience. A highlight of this work has been determining the critical role that cation-π interactions play in establishing the addictive properties of nicotine. Dougherty has attended many Gordon Conferences and chaired the GRC on Ligand Recognition and Molecular Gating in 2004. Dougherty states, "Attending a GRC is always enlightening and stimulating, but more than once I have attended a meeting in an area that was relatively new to me, because my research was heading in a new direction. I learned a great deal and made lasting connections with leaders in the field. Going forward, this potential for (re)invigorating a research program should be encouraged by continuing to ensure strong participation by younger scientists and also, when possible, opening slots to out-of-field researchers, who would provide interesting new perspectives to the meeting and could move a research area in a new direction."

Donald Hilvert
ETH Zurich

Term: November 2015-2021

Donald Hilvert is Professor and Chair of the Department of Chemistry and Applied Biosciences at the ETH Zurich, Switzerland. Hilvert obtained his Ph.D. in Chemistry from Columbia University. Following postdoctoral work at Rockefeller University, Hilvert joined the faculty of the Scripps Research Institute in La Jolla, California in 1986. Since October 1997, Hilvert has been Professor in the Laboratory of Organic Chemistry at the ETH Zurich. Hilvert's research program focuses on understanding how enzymes work and evolve and on mimicking the properties of these remarkable catalysts through design. Hilvert's work has been recognized by a number of awards, including the Arthur C. Cope Scholar Award from the American Chemical Society, the Pfizer Award in Enzyme Chemistry, and the Protein Society Emil Thomas Kaiser Award. Hilvert has also received an honorary doctorate from Uppsala University. In addition to participating in 30 Gordon Research Conferences over the years, Hilvert co-chaired the Bioorganic GRC in 1998 and the Biocatalysis GRC in 2006. Such conferences provide scientists an invaluable forum for discussing topical research developments in their own fields as well as exciting opportunities for reaching across traditional scientific boundaries. Hilvert states, "Although the inclusiveness of GRCs is already admirable, their attractiveness for the international scientific community could still be enhanced and ongoing efforts to engage scientists just starting their careers, as well as those active in non-academic settings, further expanded."

David J. Glass

Term: November 2016-2022

David J. Glass is Executive Director and Head of the Aging Group at the Novartis Institutes for Biomedical Research. He’s an MD, and did his postdoctoral training at Columbia University, after he which he joined Regeneron Pharmaceuticals, and became Vice President of the Muscle Group. He joined Novartis in 2005, and founded a Muscle Group there. Novartis’ Muscle group has brought three novel pharmaceuticals to clinical trials, one of which has been declared a "breakthrough therapy" by the FDA. In 2015 he started a new group to focus on Aging-related signaling pathways, to treat age related disease. In addition, Glass is interested in increasing education related to the correct design of experiments. He started a course at Harvard Medical School, "Experimental Design for Biologists" and wrote a book of that title. Glass has attended many Gordon Research Conferences. He recognizes the great importance of high-quality research meetings. Glass states, "The GRC conferences are important to alert scientists to the latest highlights in their fields. They should be open to new scientists and new ideas. It is extremely important to have a forum for the free exchange of the latest scientific data. These conferences should also help to promote the best methods in science, and to challenge entrenched dogma with improved methods and new findings. Future conferences should strive to bring together scientists who in the past have not interacted at meetings, allowing for cross-fertilization of disciplines and ideas. Also new fields and technologies should be well-represented. It’s also very important to promote pure basic research, since one can never predict from where the next breakthrough will emerge". As an industry scientist, Glass still greatly appreciates pure basic research, in addition to the importance of translating important findings to human disease.

Mark A. Murcko
Relay Therapeutics

Term: November 2016-2022

Mark Murcko is a chemist who has contributed to seven marketed drugs and several others currently in mid-stage clinical trials. Murcko was Chair of the 2013 Medicinal Chemistry GRC and co-organizer of the 2008 ACS National Medicinal Chemistry Symposium. He is a co-inventor on 50 issued and pending patents, a co-author or 85 scientific articles (H-index = 50), and has delivered roughly 200 invited lectures. Murcko has attended roughly 30 GRCs and has been an invited speaker at GRCs covering six different disciplines. Murcko is the Chief Scientific Officer of Relay Therapeutics in Cambridge, Massachusetts and is also a Senior Lecturer in the Department of Biological Engineering at MIT. He serves on numerous scientific advisory boards and corporate boards of directors for a diverse range of companies in the biomedical space. Murcko received his PhD from Yale and then worked at Merck Sharpe & Dohme, where he contributed to the discovery of multiple clinical candidates including inhibitors of carbonic anhydrase for the treatment of glaucoma. One of these candidates, dorzolamide, was commercialized in two medicines, Trusopt and Cosopt. Trusopt was the first marketed drug in pharmaceutical history to result from a structure-based drug design program. In 1990, Murcko was a founding scientist of Vertex Pharmaceuticals and rose to be Chief Technology Officer and Chair of the Scientific Advisory Board. Murcko is a co-inventor of the HCV drug Incivek (telaprevir), as well as the HIV drugs Agenerase (amprenavir) and Lexiva (fosamprenavir). He helped to guide the early efforts of Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor / ivacaftor). He is a co-inventor of 8 other clinical candidates in multiple disease areas and was responsible for starting many of Vertex's more recent programs that have led to active clinical candidates, notably Vertex’s influenza drug VX-787 currently in phase II, and Vertex’s cancer drug VX-970, currently in Phase I. Murcko states, "The GRC mission statement demonstrates the commitment of the organization to addressing a wide range of critical issues. To further strengthen the pre-eminent role of the GRC, I would focus on a few key strategic questions: (1) How can the global reach of the GRC be extended? (2) How can more interdisciplinary science be encouraged? (3) How can information technologies be used to enhance the value of the Conferences both to the scientific community and the broader population?"

Elsa Reichmanis
Georgia Institute of Technology

Term: November 2016-2019

Elsa Reichmanis is Brook Byers Professor of Sustainability and Professor, School of Chemical and Biomolecular Engineering of the Georgia Institute of Technology. Prior to joining Georgia Tech, she was Bell Labs Fellow and Director of the Materials Research Department, Bell Labs, Murray Hill, NJ. She received her Ph.D. and BS in Chemistry from Syracuse University. She is a member of the National Academy of Engineering and has received several awards for her work, including the American Chemical Society Award in Applied Polymer Science and the Society of Chemical Industry Perkin Medal. She has also been active in professional societies; she served as 2003 President of the ACS, and has participated in many National Research Council activities. Her research, at the interface of chemical engineering, chemistry, materials science, optics, and electronics, spans from fundamental concept to technology development and implementation. Her interests include the chemistry, properties and application of materials technologies for photonic and electronic applications, with particular focus on polymeric and nanostructured materials for advanced technologies. Currently, efforts aim to identify fundamental parameters that will enable sub-nanometer scale dimensional control of organic, polymer and/or hybrid active materials. Reichmanis has attended several Gordon Research Conferences, and recognizes the impact these conferences have in a broad range of scientific disciplines. Importantly, they bring scientists from the academic, industrial and government sectors together to discuss the latest discoveries. They also play a significant role in promoting early career investigators. Reichmanis states, "The GRC provides a forum for the open exchange of current scientific results and ideas. They also foster an atmosphere of openness and collaboration among scientists from different disciplines. As science becomes a truly global enterprise, it is important for the GRC to lead in addressing the new challenges and needs of the community".

Albert Cheung Hoi Yu
Neuroscience Research Institute, Peking University

Term: November 2016-2019

Albert Cheung-Hoi Yu is Professor and Vice Director of the Neuroscience Research Institute, Professor and Chief of Laboratory of Translational Medicine in Institute of Systems Biomedicine at Peking University. He received his PhD in Pharmacology from the University of Saskatchewan, Canada. He then moved to work at UCSF and Stanford University before returning to Hong Kong and Beijing to work in Hong Kong University of Science and Technology and Peking University. His research focus on the functional studies of astrocyte under both physiological and pathological conditions. He has published over 5 books in the field of astrocyte research and over 150 peer-reviewed scientific articles. He is the recipient of the 2004 Hong Kong Award for Industry, 2008 Asian Knowledge Management Award – Leadership and 2009 Asia Pacific Frost & Sullivan Product Differentiation Excellence Award for In-Vitro Diagnostics. He is currently serving as Chairman of Hong Kong Biotechnology Organization, Director of Asia Fund for Cancer Research, Vice President of The Chinese Neuroscience Society, Member of HKSAR Commission on Strategic Development, Chairman of Hong Kong Council for Testing and Certification and Director of Hong Kong Science and Technology Parks Corporation. He is honored to serve on the Board of Trustees of the Gordon Research Conferences and has participated in numerous Gordon Research Conferences. Yu states, "He recognizes the profound impact of GRC conferences in fostering the development of scientific research and offering a crucial platform for young investigators in China to develop into leaders in their research field. He has extensive experience in chairing and organizing over 20 international conferences. Every effort he spent is to accelerate scientific blossom in Hong Kong and China. He looks forward to seeing GRC conferences to grow in Asia and become a cultivation ground for all young scientists in China".

© 2017 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter